Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3246457 | 0.85 | KMT2A (0.47) | MEN1KMT2ASMN1; SMN2PIM1MRGPRX4 | |
| SCHEMBL3320334 | 0.83 | KDM4E (0.42) | SMN1; SMN2MRGPRX4DHODHHSP90AB1CSNK1D | |
| SCHEMBL2331533 | 0.81 | HSP90AB1 (0.43) | MEN1KMT2ADHODHHSP90AB1 | |
| SCHEMBL9682203 | 0.74 | MEN1 (0.71) | MEN1KMT2ASMN1; SMN2MRGPRX4L3MBTL1 | |
| SCHEMBL378549 | 0.72 | VNN1 (0.52) | MEN1KMT2ASMN1; SMN2MRGPRX4KDM5A | |
| SCHEMBL11462809 | 0.72 | CYP11B1 (0.50) | SMN1; SMN2TP53HSP90AB1 | |
| SCHEMBL27237496 | 0.71 | MEN1 (0.66) | MEN1KMT2ASMN1; SMN2MRGPRX4L3MBTL1 | |
| SCHEMBL27822162 | 0.71 | DHODH (0.44) | PIM1MRGPRX4DHODHTP53TRPV1 | |
| SCHEMBL2176876 | 0.70 | CYP11B1 (0.51) | SMN1; SMN2TP53HSP90AB1 | |
| SCHEMBL11469405 | 0.70 | CYP11B1 (0.51) | MEN1KMT2ASMN1; SMN2TP53HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358677-B1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8188090-B2 | Naphthylacetic acids | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| CN-102216273-A | Naphthylacetic acids used as crth2 antagonists or partial agonists | HOFFMANN LA ROCHE (CH) | 2011-10-12 | — | — | CN | disclosed |
| EP-2358677-A1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | FIROOZNIA FARIBORZ | 2010-05-20 | — | — | US | disclosed |
| WO-2010055006-A1 | NAPHTHYLACETIC ACIDS USED AS CRTH2 ANTAGONISTS OR PARTIAL AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125061-A1 | NAPHTHYLACETIC ACIDS | HRH2, HRH1, HRH3 | MEN1 3561/4885KMT2A 2023/4885SMN1; SMN2 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.